Dr. Alex Kuta joined uniQure in January 2017 as Senior Vice President, Regulatory Affairs. In his current role as Executive Vice President, Operations, he is responsible for global quality and regulatory affairs, as well as GMP manufacturing at uniQure’s state-of-the-art facility in Lexington, Massachusetts.
He joined uniQure from EMD Serono, where he served as Vice President of Research & Development Global Regulatory Affairs and where he was a member of the U.S. Leadership Team. In this role, he was responsible for driving the strategic direction of EMD Serono’s regulatory efforts in immune-mediated diseases, oncology and regulatory CMC, as well as strengthening interactions with the U.S. Food and Drug Administration (FDA).
Prior to joining EMD Serono, Dr. Kuta was Vice President of Global Regulatory Affairs and a member of the Executive Leadership Team at Lantheus Medical Imaging. His previous experience includes senior roles at AMAG Pharmaceuticals and at Genzyme Corporation, where he served for 15 years in regulatory leadership positions of increasing responsibility. Prior to joining industry, he was Chief of the Cytokine and Gene Therapy Branch in the Center for Biologics at FDA. Dr. Kuta has also served as a member of the BIO Regulatory Affairs Leadership Committee, Cell and Gene Therapy Working Group and the ICH Gene Therapy Working Group.
Dr. Kuta holds a Bachelor of Science degree from Saint John's University and a Ph.D. from Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his post-doctoral studies at the National Cancer Institute/ National Institutes of Health.
What is Alexander Edward Kuta, III's net worth?
The estimated net worth of Alexander Edward Kuta, III is at least $435,636.42 as of March 7th, 2023. Dr. Kuta, III owns 90,381 shares of uniQure stock worth more than $435,636 as of April 23rd. This net worth evaluation does not reflect any other assets that Dr. Kuta, III may own. Learn More about Alexander Edward Kuta, III's net worth.
How do I contact Alexander Edward Kuta, III?
Has Alexander Edward Kuta, III been buying or selling shares of uniQure?
Alexander Edward Kuta, III has not been actively trading shares of uniQure over the course of the past ninety days. Most recently, Alexander Edward Kuta III sold 585 shares of the business's stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $21.36, for a transaction totalling $12,495.60. Following the completion of the sale, the vice president now directly owns 90,381 shares of the company's stock, valued at $1,930,538.16. Learn More on Alexander Edward Kuta, III's trading history.
Who are uniQure's active insiders?
Are insiders buying or selling shares of uniQure?
In the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 81,031 shares worth more than $683,268.05. The most recent insider tranaction occured on February, 26th when COO Pierre Caloz sold 9,455 shares worth more than $61,173.85. Insiders at uniQure own 4.1% of the company.
Learn More about insider trades at uniQure. Information on this page was last updated on 2/26/2024.
